AIBN alum Dr Feifei Liu is helping guide potential cancer therapies through the complex drug-development pipeline, driven by the hope that one may ultimately change a patient’s life.
As Director of Translational Science at AdvanCell, AIBN alum Dr Feifei Liu leads the biological evaluation of potential radiopharmaceutical therapies, helping determine which candidates are strong enough to continue towards clinical development.
As she reflects on her journey from AIBN to industry, Dr Liu explains how a long-held ambition to follow the complete life cycle of a drug continues to shape her career.

From thousands of possibilities to one
AdvanCell is a clinical-stage radiopharmaceutical company developing a portfolio of cancer therapies using Targeted Alpha Therapy, which delivers high-energy radiation directly to tumour cells using targeted molecules.
After initial screening of these molecules, the most promising candidates come to Dr Liu’s team for in-depth biological testing to further narrow down the selection.
“It is fascinating to me – the process of starting with thousands of drug candidates, then screening them down to hundreds, then tens, and finally one.”
Dr Liu’s career goal is to contribute to the entire life cycle of a drug, from its earliest discovery to its use in patients.
And at AdvanCell, she is already gaining experience across several stages of that journey.
“I’m grateful for this opportunity – lots of people working in this field will probably never have this experience in their entire career.”
A curiosity that led to AIBN
Curiosity about how new drugs are discovered and developed led Dr Liu to pursue a PhD in research.
Before her PhD, Dr Liu already had over 6 years of experience working in the pharmaceutical industry both in China and Sydney – in production and quality assurance.
“I had seen the commercial manufacturing side of drug products but I was curious about how drugs are discovered at the beginning of the life cycle, and I wanted to enter the research world to find out.”
Dr Liu was attracted to AIBN by its breadth of research, specialist facilities and strong industry links.
“The opportunity to work in an environment that bridges scientific research and its practical applications was definitely a factor in my decision to join AIBN – I was keen to gain a broader perspective on how research can contribute to advancing healthcare.”
The diversity of expertise was another draw, with researchers from many disciplines working under one roof.
“I learnt so much during my PhD, being in this diverse environment – working alongside experts in nanoparticles, imaging, immunology or molecular biology – I established so many connections, people who I can still call on today.”

A supportive environment
Dr Liu remembers that AIBN’s advanced research infrastructure came with something equally valuable: specialist staff willing to provide training and practical help.
“Sometimes I needed help at the last minute, I needed an experiment done today or had a problem with a equipment, they would always step in.”
Dr Liu recalls the support she received in her research group as “amazing”, with colleagues creating a friendly and supportive environment.
“I didn’t have a strong research background when I started my PhD, so I relied on technical training from my peers – although everyone was busy with their own projects, someone would always jump in and help.”
She particularly remembers the support of her PhD supervisor, now AIBN Director, Professor Kristofer Thurecht, when she was going through a tough phase and how important it was.
“I had a period of time without progress and I was struggling – I felt like he understood my challenges and I was encouraged to keep going.”
Becoming an industry-ready researcher
During her PhD, Dr Liu was part of the ARC Training Centre for Innovation in Biomedical Imaging Technology, known as CIBIT.
Through the centre, she worked with start-up company InterK Peptide Therapeutics Ltd on an industry-linked research project.
The company had a promising drug candidate but needed to improve its pharmacokinetic profile: how the drug is absorbed, distributed, metabolised and excreted by the body.
Dr Liu applied the nanotechnology skills developed through her PhD to the challenge.
She credits the experience with helping her become an ‘industry-ready researcher’.
“All the skills I have learned through my PhD – from drug discovery, to validating drug function and pharmacokinetic profile – I took that knowledge with me to AdvanCell.”

A smooth transition into industry
Dr Liu never expected to land a job immediately after her PhD through an AIBN connection.
At the time of her graduation, Dr Liu was working as a research assistant in Professor Thurecht’s lab on AdvanCell projects, directly generating raw data.
“AdvanCell knew the quality of my work, they knew I was about to graduate and that’s how the conversation started.”
“And for me, when they offered me the job, I knew the company, knew my values aligned with theirs and knew some of the people I’d be working with – it was a smooth transition.”
Dr Liu’s experience reflects a broader relationship between AIBN and AdvanCell.
In the early stages of the company, AIBN was critical to AdvanCell’s growth, providing both infrastructure and research expertise.
This connection remains strong.
Like Dr Liu, many AdvanCell staff have previously worked at AIBN and she co-supervises a PhD student across the two organisations, collaborates on research programs and helps accommodate AIBN students for industry internships.
Leading with hope

Building her team has been one of Dr Liu’s proudest achievements.
After joining as the department’s second team member, she helped establish the training and management systems supporting its growth.
As her role at AdvanCell has grown, Dr Liu has continued to learn as a leader and manager.
Becoming a mother has also shaped her approach to leadership, giving her a deeper appreciation of the different demands people balance outside work.
“Now I understand more about work-life balance and how everyone has to manage their life/work differently and it has made me a better manager”
Dr Liu has always tried to soak up as much knowledge as possible, knowing that its value may only become clear years later.
“I'm always learning, I'm still absorbing, I’m like a sponge for knowledge.”
Over the next decade, Dr Liu hopes to see a drug in development receive regulatory approval and reach patients.
She acknowledges that drug development can be challenging and that years of effort may need to begin again, but the possibility of meaningful patient impact provides her with a continuing sense of purpose.
“The work we are doing day by day, little by little, I hope that one day we will change a patient’s life – that keeps me motivated to keep trying.”
Join The Network
Stay on top of our industry news and developments, events and opportunities, by joining The Network
Sign up today